The use of OKT3 in steroid-resistant rejections following cadaveric kidney transplantation

B Rosenkranz; W Niebel; K Albrecht; K Wagner; T Philipp; F W Eigler

doi:10.1007/978-3-642-77423-2_36

The use of OKT3 in steroid-resistant rejections following cadaveric kidney transplantation

Transpl Int. 1992:5 Suppl 1:S112-3. doi: 10.1007/978-3-642-77423-2_36.

Authors

B Rosenkranz¹, W Niebel, K Albrecht, K Wagner, T Philipp, F W Eigler

Affiliation

¹ Department for General Surgery, University Hospitals, D-4300 Essen, FRG.

PMID: 14621750
DOI: 10.1007/978-3-642-77423-2_36

Abstract

OKT3 has been proved to be effective in the treatment of steroid-resistant rejection after renal allograft transplantation. We investigated the clinical course of OKT3 recipients to find out in which cases of steroid resistance OKT3 therapy might be ineffective.

MeSH terms

Adult
Animals
Cadaver
Female
Graft Rejection / prevention & control*
Histocompatibility Testing
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use
Kidney Transplantation / immunology*
Kidney Transplantation / mortality
Kidney Transplantation / pathology
Male
Muromonab-CD3 / therapeutic use*
Steroids / adverse effects*
Survival Analysis
Time Factors
Tissue Donors

Substances

Immunosuppressive Agents
Muromonab-CD3
Steroids